In what signifies the end of a challenging regulatory journey, Scholar Rock secured an FDA approval for its spinal muscular ...
GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk. | GSK is ...
GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an ...
A higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ...
Commercial strategies are often developed months before execution, but today's life sciences environment rarely stands still.
Akeso and Summit Therapeutics’ ivonescimab reduced the risk of death by 27% compared with Keytruda in patients with treatment ...
The fact that Gilead Sciences’ Trodelvy failed as a first-line treatm | Newly revealed global phase 3 data from Merck and ...
The ink was barely dry on the FDA approval letter for AstraZeneca’s Etcamah before the oral SERD suffered a key clinical ...
Takeda's long-time R&D chief Andy Plump will retire. Daiichi Sankyo beat back a $1.3 billion damage claim in a lawsuit.
In his first interview after taking the reins of the FDA’s Oncology Center of Excellence (OCE), Angelo de Claro, M.D., is ...
Following formal sign-off from the FDA, Handa Pharmaceuticals’ branded drug reformulation strategy has paid off for a third ...
With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results